A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC
NCT ID: NCT00483821
Last Updated: 2012-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
165 participants
OBSERVATIONAL
2004-05-31
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is evaluating the medical charts of patients with primary head and neck cancer who have undergone neck dissection after complete response to chemotherapy and radiation therapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Secondary Lymphedema on Symptoms, Functional Status, and Quality of Life After Treatment in Patients With Head and Neck Cancer
NCT01098669
Chemo-embolization for Head and Neck Cancer
NCT04595981
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
NCT02126969
Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer
NCT00840814
Discovering Factors in Head and Neck Cancer Patients' Clinical Study Experiences
NCT05801770
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Perform a retrospective analysis, by medical chart review, of patients with primary squamous cell carcinoma of the head and neck who underwent neck dissection following complete response to chemoradiotherapy.
* Determine whether the role of a post-chemoradiotherapy neck dissection affects the outcome of the patient's disease, in terms of overall survival, disease-free survival, and recurrence rates.
OUTLINE: This is a pilot, retrospective study.
Patients who have undergone neck dissection after achieving a complete clinical and radiological response to chemoradiotherapy are compared to patients who did not. Data are gathered by medical chart review.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
medical chart review
medical chart review
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Oral cavity
* Oropharynx
* Hypopharynx
* Larynx
* Complete response achieved after treatment with chemoradiotherapy
Exclusion Criteria
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Vanderbilt-Ingram Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Barbara Murphy, MD
Professor of Medicine; Director, Cancer Supportive Care Program; Director, Head and Neck Research Program; Medical Oncologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barbara Murphy, MD
Role: STUDY_CHAIR
Vanderbilt-Ingram Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VU-VICC-HN-0435
Identifier Type: -
Identifier Source: secondary_id
VU-VICC-IRB-040428
Identifier Type: -
Identifier Source: secondary_id
VICC HN 0435
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.